<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>PFE on Deep Analyst AI</title><link>https://deepanalyst.ai/tags/PFE/</link><description>Recent content in PFE on Deep Analyst AI</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Tue, 17 Mar 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://deepanalyst.ai/tags/PFE/rss.xml" rel="self" type="application/rss+xml"/><item><title>Pharma’s FOMO Fever: Why Pfizer Is Sitting Out Moderna’s mRNA Rager</title><link>https://deepanalyst.ai/posts/2026/03/pfe-pharma-s-fomo-fever-why-pfizer-is-sitting-out-moderna-s-mrna-rager/</link><pubDate>Tue, 17 Mar 2026 00:00:00 +0000</pubDate><guid>https://deepanalyst.ai/posts/2026/03/pfe-pharma-s-fomo-fever-why-pfizer-is-sitting-out-moderna-s-mrna-rager/</guid><description>Pharma’s FOMO Fever: Why Pfizer Is Sitting Out Moderna’s mRNA Rager The healthcare sector is throwing a rager, and it feels like everyone got an invite but Pfizer. While Moderna (MRNA) is doing keg stands after an 83% surge, fueled by a wildly fortunate FDA reversal on its mRNA flu shot application, Novartis (NVS) is making it rain with a $12 billion buyback. Meanwhile, Pfizer (PFE) is parked in the corner, nursing a warm seltzer and talking about its sensible dividend yield.</description></item></channel></rss>